inclusion criteria: 1. confirmed sars-cov-2 infection, defined as rt-pcr provincial laboratory confirmation; 2. time from patient reported first symptoms date of enrollment \<7 days; 3. must be experiencing at least 1 covid-19 symptom that is either continuing or increasing in severity 4. severe disease risk factor requirements: i) age 18-49: ≥3 risk factors ; ii) age 50-59: ≥2 risk factors; iii) age 60-69: ≥1 risk factor; iv) pregnant or age 70+: no requirements 5. participants must agree to: i) use assigned medication for a maximum of 60 days or until relief of symptoms; and ii) complete the flu-pro plus and spo2 daily diary and other study assessments during the course of follow-up.

inclusion criteria: 1. confirmed sars-cov-2 infection, defined as rt-pcr provincial laboratory confirmation; 2. time from patient reported first symptoms date of enrollment \<7 days; 3. must be experiencing at least 1 covid-19 symptom that is either continuing or increasing in severity 4. severe disease risk factor requirements: i) age 18-49: ≥3 risk factors ; ii) age 50-59: ≥2 risk factors; iii) age 60-69: ≥1 risk factor; iv) pregnant or age 70+: no requirements 5. participants must agree to: i) use assigned medication for a maximum of 60 days or until relief of symptoms; and ii) complete the flu-pro plus and spo2 daily diary and other study assessments during the course of follow-up.

inclusion criteria: confirmed sars-cov-2 infection, defined as rt-pcr provincial laboratory confirmation; time from patient reported first symptoms date of enrollment <7 days; must be experiencing at least 1 covid-19 symptom that is either continuing or increasing in severity severe disease risk factor requirements: i) age 18-49: ≥3 risk factors ; ii) age 50-59: ≥2 risk factors; iii) age 60-69: ≥1 risk factor; iv) pregnant or age 70+: no requirements participants must agree to: i) use assigned medication for a maximum of 60 days or until relief of symptoms; and ii) complete the flu-pro plus and spo2 daily diary and other study assessments during the course of follow-up.

inclusion criteria: confirmed sars-cov-2 infection, defined as rt-pcr provincial laboratory confirmation; time from patient reported first symptoms date of enrollment <7 days; must be experiencing at least 1 covid-19 symptom that is either continuing or increasing in severity severe disease risk factor requirements: i) age 18-49: ≥3 risk factors ; ii) age 50-59: ≥2 risk factors; iii) age 60-69: ≥1 risk factor; iv) pregnant or age 70+: no requirements participants must agree to: i) use assigned medication for a maximum of 60 days or until relief of symptoms; and ii) complete the flu-pro plus and spo2 daily diary and other study assessments during the course of follow-up.

inclusion criteria: confirmed sars-cov-2 infection, defined as rt-pcr provincial laboratory confirmation; time from a positive test result to date of enrollment <1 week; time from patient reported first symptoms date of enrollment <14 days; able to complete weekly follow-up assessments and agrees to provide them on a weekly basis; agrees to use assigned medication for the 60 days prescribed; and informed consent is obtained.

inclusion criteria: confirmed sars-cov-2 infection, defined as rt-pcr provincial laboratory confirmation; time from a positive test result to date of enrollment <1 week; time from patient reported first symptoms date of enrollment <14 days; able to complete weekly follow-up assessments and agrees to provide them on a weekly basis; agrees to use assigned medication for the 60 days prescribed; and informed consent is obtained.

inclusion criteria: 1. confirmed sars-cov-2 infection, defined as rt-pcr provincial laboratory confirmation; 2. time from a positive test result to date of enrollment <1 week; 3. time from patient reported first symptoms date of enrollment <14 days; 4. able to complete weekly follow-up assessments and agrees to provide them on a weekly basis; 5. agrees to use assigned medication for the 60 days prescribed; and 6. informed consent is obtained.

inclusion criteria: 1. confirmed sars-cov-2 infection, defined as rt-pcr provincial laboratory confirmation; 2. time from a positive test result to date of enrollment <1 week; 3. time from patient reported first symptoms date of enrollment <14 days; 4. able to complete weekly follow-up assessments and agrees to provide them on a weekly basis; 5. agrees to use assigned medication for the 60 days prescribed; and 6. informed consent is obtained.